Buspirone is NOT Recommended for Agitation in Dementia
Buspirone should not be used as a primary treatment for agitation in dementia patients. While the FDA label indicates buspirone is approved only for generalized anxiety disorder (GAD)—not for behavioral disturbances in dementia—and current guidelines do not support its use for this indication 1, 2.
Why Buspirone is Not the Right Choice
Lack of Guideline Support
The 2014 multidisciplinary expert panel on neuropsychiatric symptoms of dementia does not include buspirone among recommended pharmacologic interventions 1. The most recent 2025 guidelines on severe agitation in older adults similarly do not mention buspirone as an evidence-based option 3.
Limited and Low-Quality Evidence
The available research consists only of:
- Small open-label studies (10-26 patients) from the 1990s 4, 5, 6
- One retrospective chart review from 2017 with 179 patients 7
- No recent randomized controlled trials
- No FDA approval for this indication 2
The 2017 retrospective study showed 68.6% response rates at mean doses of 25.7 mg/day, but this is uncontrolled data with high risk of bias 7. The 1996 double-blind comparison to haloperidol (n=26) showed some benefit for tension/anxiety but lacked a placebo arm, making interpretation difficult 5.
What to Use Instead
First-Line: Non-Pharmacologic Approaches
Always start with non-pharmacologic interventions unless there is imminent danger 1. These include:
- Identifying and addressing unmet needs (pain, hunger, toileting)
- Environmental modifications
- Person-centered communication strategies
- Sensory interventions
Second-Line: Evidence-Based Pharmacologic Options
When medications become necessary, consider these options based on the specific presentation:
For General Agitation:
- Citalopram: Supported by evidence for agitation in Alzheimer's disease 8, 9
- Monitor QTc interval (risk of prolongation)
- Start low, titrate slowly
For Aggression/Psychosis:
Risperidone: Conditionally recommended for severe aggression and psychosis 8, 9
- Use lowest effective dose
- Time-limited trial (weeks, not months)
- Black box warning: increased mortality risk in elderly with dementia
Quetiapine: Showed lower adverse event rates (OR 0.27) compared to haloperidol in the 2025 systematic review 3
For Severe Emergency Agitation:
- Avoid benzodiazepines, especially midazolam (53% adverse event rate, OR 5.25 for harm vs. haloperidol) 3
Cognitive Enhancers:
- Cholinesterase inhibitors or memantine: Should be optimized first, as they may reduce behavioral symptoms 8, 9
Critical Safety Considerations for Buspirone (If Considered Despite Lack of Evidence)
If you still consider buspirone off-label:
Dosing Cautions
- Severe hepatic/renal impairment: Cannot be recommended due to increased plasma levels and prolonged half-life 2
- Elderly patients: No dose adjustment needed per FDA label, but start conservatively 2
- Typical doses in dementia studies: 15-60 mg/day in divided doses 7, 4
Drug Interactions
- Major CYP3A4 inhibitors (ketoconazole, itraconazole, nefazodone): Reduce buspirone dose to 2.5 mg daily due to 13-20 fold increases in drug levels 2
- Grapefruit juice: Avoid (9-fold increase in AUC) 2
- Warfarin: Monitor INR closely (case report of prolonged PT) 2
Monitoring
- Discontinue 48 hours before urine catecholamine testing (false positive for pheochromocytoma) 2
Bottom Line Algorithm
- Exhaust non-pharmacologic interventions first (unless imminent danger)
- Optimize cognitive enhancers (donepezil, memantine)
- For persistent agitation: Trial citalopram with QTc monitoring
- For severe aggression/psychosis: Consider low-dose risperidone or quetiapine with informed consent about mortality risk
- Buspirone: Reserve only for cases where anxiety is the predominant feature and other options have failed, recognizing this is off-label use with minimal supporting evidence
The evidence for buspirone in dementia-related agitation is insufficient to recommend its routine use when better-studied alternatives exist.